Background and objectives: Migraine is a common primary headache disorder associated with neuroinflammation, with evidence implicating gut microbiota and metabolites in neurological mechanisms pathways. Since trimethylamine-N-oxide (TMAO), derived from dietary precursors by gut microbial metabolism, is associated with cardiovascular and neurodegenerative conditions, and its role in migraines is unclear, we aimed to evaluate whether serum TMAO level and related metabolites in migraine patients can be biomarkers. Methods: A total of 106 participants were enrolled, consisting of healthy controls (n=46; mean age ± SD=39±8 yr old) and migraine patients (n=60). The migraine cohort was divided into migraine with aura (n=18; mean age±SD=33±11 yr old) and migraine without aura (n=42; mean age±SD=37±10 yr old), according to the International Classification of Headache Disorders, 3rd edition (ICHD-3). Blood samples were centrifuged, stored at –80°C, and analysed for TMAO, carnitine, betaine, and choline levels using liquid chromatography–mass spectrometry (LC-MS/MS). Results: There were no significant differences between the groups for age, smoking, or body mass index (BMI). Serum TMAO levels were significantly higher in patients with migraine with aura [2.75 (1.98–3.91) ng/mL] and migraine without aura [2.85 (2.08–5.53) ng/mL] compared to controls [1.40 (1.00–3.01) ng/mL] ( P <0.001). Serum choline, betaine, and carnitine levels were significantly higher in the migraine groups (all P < 0.01). Interpretation and conclusions: These findings indicate elevated TMAO levels in patients with migraine, suggesting a possible involvement of TMAO in migraine-associated neuroinflammatory processes. Targeted studies and cohort-based investigations are needed to clarify its role in migraine and evaluate its potential as a biomarker.
Introduction: Alzheimer’s disease dementia (AD dementia) is a progressive neurodegenerative disorder associated with cognitive decline. Oxidative stress and inflammation may contribute to its pathophysiology, with clusterin (CLU) and sestrin-2 (SESN2) emerging as potential biomarkers. This study evaluated oxidative stress markers, inflammatory indices, and serum CLU and SESN2 levels in patients with AD dementia. Methods: A total of 48 patients with AD dementia and 39 healthy controls in a broadly comparable age range were enrolled from a neurology outpatient clinic. AD dementia was diagnosed according to internationally accepted clinical criteria. Cognitive function was assessed using Mini-Mental State Examination (MMSE) scores obtained at diagnosis. Serum malondialdehyde (MDA), glutathione (GSH), CLU, and SESN2 were measured, with MDA and GSH analyzed spectrophotometrically and CLU and SESN2 concentrations determined using the enzyme-linked immunosorbent assay (ELISA). Inflammatory indices were calculated from routine hematological and biochemical parameters. Results: A multivariable logistic regression model including age, MDA, and GSH showed excellent discriminatory performance for distinguishing patients with AD dementia from healthy controls. Patients with AD dementia had significantly lower SESN2 levels (p < 0.001) and higher CLU levels (p < 0.001) than controls. No significant associations were observed between inflammatory indices and the investigated clinical or biochemical variables in the AD dementia group (p > 0.05). Conclusions: Oxidative stress and altered SESN2 and CLU levels may be associated with AD dementia, whereas the inflammatory indices showed limited utility. Larger prospective studies are needed to validate these findings and clarify their clinical significance.